Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:
WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL
WT peptide #2: HLA-A24 restricted: CMTWNQMNL
WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL
WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT
Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs.

Acute Myelogenous Leukemia (AML)

Chronic Myelogenous Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Myelodysplastic Syndrome (MDS)

B Cell Malignancies

WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:
WT peptide #1: HLA-A2 restricted: RMFPNAPYL
WT peptide #2: HLA-A24 restricted: CMTWNQMNL
WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL
WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT
Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs.

WT1 derived peptides

Duke Comprehensive Cancer Center

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CmML, ALL, MDS, and B Cell Malignancies

To determine the safety and feasibility of administering WT1 peptides to subjects who have undergone autologous or allogeneic stem cell transplantation for AML, CML, ALL, B cell malignancies and myelodysplastic syndrome.

To evaluate the immune response to immunizations.

To obtain preliminary data on efficacy (PFS and OS) following immunization in those with available data.

wilms tumor/edema

A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

Najkompletnija baza ljekovitog bilja potpomognuta znanošću